Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$133.08 USD
-0.38 (-0.28%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $133.07 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 521 - 540 ( 672 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Limited News Flow Till Mid-15 NDA Filing, We Are Buyers on Weakness
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Potential Regulatory Clarity Coming Next Quarter; Reiterate NEUTRAL Rating
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
YE14 Call Scheduled for February 26th. Our Key Questions for Management...
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Assuming coverage and Downgrading to NEUTRAL with $16 PT; Best in Class Potential, but Risks Loom Large
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Overhang Gone, No Longer a One Drug Story
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Compelling EV With Three Exon- Skippers In The Clinic During 2015
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Aiming For A Class Approval For Morpholino''s in DMD
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Is Biomarin Really a Big Threat with an Inferior Drug?
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Study Underway, Limited Downside From Current Levels
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
One Small Infusion, One Giant Step Towards Validation
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D